The Food and Drug Administration (FDA) has approved Eli Lilly’s Foundayo (orforglipron), a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, which offers a noninjectable option for weight management.
Clinical data suggests the drug supports meaningful weight loss and can be taken without strict food or timing requirements, potentially improving ease of use and adherence.
The approval was expedited through the FDA’s National Priority Voucher program, a new initiative designed to speed up access to treatments addressing major public health needs.
Orforglipron’s approval highlights both the growing role of GLP-1 therapies in weight loss and the potential for faster regulatory pathways, bringing new treatments to patients sooner.
Pharmacy near me
1 thought on “FDA approves Wegovy-like GLP-1 pill, Foundayo, for weight loss”
The approval of Foundayo marks a major turning point in weight management therapies. The fact that patients can take a once-daily oral GLP-1 without strict meal timing or food restrictions addresses one of the biggest friction points of injectable options, likely boosting long-term adherence significantly.
The approval of Foundayo marks a major turning point in weight management therapies. The fact that patients can take a once-daily oral GLP-1 without strict meal timing or food restrictions addresses one of the biggest friction points of injectable options, likely boosting long-term adherence significantly.